Official ESCRS | European Society of Cataract & Refractive Surgeons



Search Title by author or title

Outcomes of combination therapy using aflibercept and dexamethasone intravitreal implant for macular edema secondary to retinal vein occlusion

Poster Details

First Author: G.Harb LEBANON

Co Author(s):    W. Harb   G. Chidiac                 

Abstract Details


To evaluate the efficacy of the combination therapy of intravitreal aflibercept 2mg (Eylea®) and a sustained-release dexamethasone 0.7mg intravitreal implant (Ozurdex®) in providing a prolonged effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (RVO).


Levant Hospital.


36 eyes with ME due to RVO were studied over 12-month. All patients were treated with an Eylea injection followed 2 weeks later by an Ozurdex injection. The same cycle was repeated if BCVA decreased by 6 or more Snellen letters from the best measurement and/or if CMT increased by >50 μm from the lowest measurement. CMT, BCVA and IOP were measured 6 weeks after the beginning of each cycle and subsequently every 4 weeks until retreatment is needed. The primary outcome measure was the time to retreatment. The secondary outcome measures included CMT, BCVA and IOP.


7 patients (19.44%) needed no retreatment after one-year follow-up. 29 patients (80.56%) needed ≥1 retreatment, and the first reinjection was at 142.17±39.13 days. There was a significant peak decrease in CMT from 482.44±79.78 μm at baseline to 209.78±13.14 μm (P<0.0001). In addition, mean BCVA improved from initially 0.706±0.23 logarithm of the minimum angle of resolution (logMAR) units to a maximum of 0.336±0.09 logMAR units during the study period (P<0.0001). An increase of IOP was seen in 7 patients out of 36 (19.44%) and was controlled by topical treatment.


Aflibercept with dexamethasone implants provided a predictable duration of effect with low intravitreal retreatment rates at first year, and achieved significant anatomical and visual outcomes in eyes with ME secondary to RVO.

Financial Disclosure:


Back to Poster listing